Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Colorectal cancer is the second-leading cause of cancer related death in the U.S., with nearly 53,0001 fatalities expected in 2025. While the burden of this disease is significant, advancements in ...

Atezolizumab plus mFOLFOX6 is a practice-changing and new standard treatment for patients with dMMR stage III colon cancer,” said Frank Sinicrope, MD.